Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
Ismail RK, Suijkerbuijk KPM, de Boer A, van Dartel M, Hilarius DL, Pasmooij AMG, van Zeijl MCT, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest H, van den Eertwegh AJ, Wouters MWJM. Ismail RK, et al. Among authors: vreugdenhil a. Melanoma Res. 2022 Dec 1;32(6):460-468. doi: 10.1097/CMR.0000000000000832. Epub 2022 Sep 5. Melanoma Res. 2022. PMID: 35703270 Free PMC article.
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
Ismail RK, Sikkes NO, Wouters MWJM, Hilarius DL, Pasmooij AMG, van den Eertwegh AJM, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije BJ, van der Veldt AAM, Vreugdenhil A, van Dartel M, de Boer A. Ismail RK, et al. Among authors: vreugdenhil a. Melanoma Res. 2021 Feb 1;31(1):58-66. doi: 10.1097/CMR.0000000000000707. Melanoma Res. 2021. PMID: 33351553 Free PMC article.
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: vreugdenhil a. Br J Cancer. 2021 Mar;124(7):1222-1230. doi: 10.1038/s41416-020-01229-1. Epub 2021 Jan 26. Br J Cancer. 2021. PMID: 33495600 Free PMC article.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije BJ, van der Veldt AAM, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: vreugdenhil a. Br J Cancer. 2021 May;124(10):1746. doi: 10.1038/s41416-021-01312-1. Br J Cancer. 2021. PMID: 33723402 Free PMC article. No abstract available.
Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokx WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, Blank CU, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: vreugdenhil a. Eur J Cancer. 2021 Nov;158:234-245. doi: 10.1016/j.ejca.2021.08.044. Epub 2021 Sep 29. Eur J Cancer. 2021. PMID: 34600790 Free article.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: vreugdenhil a. Br J Cancer. 2022 May;126(9):1362. doi: 10.1038/s41416-022-01772-z. Br J Cancer. 2022. PMID: 35256756 Free PMC article. No abstract available.
CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma.
Ter Maat LS, van Duin IAJ, Elias SG, Leiner T, Verhoeff JJC, Arntz ERAN, Troenokarso MF, Blokx WAM, Isgum I, de Wit GA, van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, van den Eertwegh FJM, de Groot JWB, Piersma D, Vreugdenhil A, Westgeest HM, Kapiteijn E, van Diest PJ, Pluim JPW, de Jong PA, Suijkerbuijk KPM, Veta M. Ter Maat LS, et al. Among authors: vreugdenhil a. Eur J Cancer. 2023 May;185:167-177. doi: 10.1016/j.ejca.2023.02.017. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36996627 Free article.
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, Van Rheenen PF, Schweizer JJ, Hoekstra JH, Norbruis OF, Tjon A Ten WE, Vreugdenhil AC, Deckers-Kocken JM, Gijsbers CF, Escher JC, De Ridder L. De Bie CI, et al. Among authors: vreugdenhil ac. Aliment Pharmacol Ther. 2011 Jan;33(2):243-50. doi: 10.1111/j.1365-2036.2010.04507.x. Epub 2010 Nov 14. Aliment Pharmacol Ther. 2011. PMID: 21083595 Free article.
159 results